維基百科

阿那白滯素

阿那白滯素（Anakinra），以Kineret名稱出售。是一種治療類風濕性關節炎, 隱熱蛋白相關週期性綜合症（英語：cryopyrin-associated periodic syndrome）、家族性地中海熱（英語：familial Mediterranean fever）、成人史迪爾氏病的生物製藥[3]。是人類白細胞介素1受體拮抗劑（英語：interleukin 1 receptor antagonist）蛋白質的重組及修改版本[3] It is marketed by Swedish Orphan Biovitrum（英語：Swedish Orphan Biovitrum）.[1]。可由皮下注射[2]。

阿那白滯素
臨床資料
商品名（英語：Drug nomenclature）Kineret
AHFS/Drugs.comMonograph
MedlinePlusa602001
核准狀況
懷孕分級
給藥途徑皮下注射
ATC碼
法律規範狀態
法律規範
藥物動力學數據
生物利用度95%
藥物代謝predominantly kidney
生物半衰期4-6 hrs
識別資訊
  • Recombinant human Interleukin-1 receptor antagonist protein; syn. N2-l-methionyl-interleukin 1 receptor antagonist (human isoform x reduced)
CAS號143090-92-0  checkY
DrugBank
ChemSpider
  • none
UNII
KEGG
ChEMBL
化學資訊
化學式C759H1186N208O232S10
摩爾質量17,257.66 g·mol−1

醫療用途

在疾病緩解抗風濕藥（英語：disease-modifying antirheumatic drug）治療失敗後，阿那白滯素被用作二線治療控制類風濕性關節炎[1][2]。可與某些DMARD結合使用[1][2][4]。

用於患有隱熱蛋白相關週期性綜合症（英語：cryopyrin-associated periodic syndrome）的人，包括新生兒多系統炎症性疾病（英語：neonatal-onset multisystem inflammatory disease）[1][2]。

已隱藏部分未翻譯內容，歡迎參與翻譯。

用於治療Schnitzler綜合症（英語：Schnitzler syndrome）（在美國不符合標籤）。[5] Its response rate is such that it has been suggested that "Treatment failures should lead to reconsider the diagnosis."[6]

仿單標示外使用, it is used to treat 幼年特發性關節炎 (SJIA), 痛風, 二水合焦磷酸鈣晶體沉積病 (CPPD), 貝賽特氏症, 強直性脊柱炎, 葡萄膜炎, and other 自身炎症性疾病.[7]

In December 2021, the 歐洲藥品管理局 authorized the use of anakinra "to treat 2019冠狀病毒病 in adults with pneumonia requiring supplemental oxygen (low or high flow oxygen) and who are at risk of developing severe respiratory failure, as determined by blood levels of a protein called suPAR (soluble urokinase plasminogen activator receptor) of at least 6 ng per ml."[3][8][9] In November 2022, the United States 美國食品藥品監督管理局 approved its use under an 緊急使用授權 "for the treatment of COVID-19 in hospitalized adults with pneumonia requiring supplemental oxygen (low- or high-flow oxygen) who are at risk of progressing to severe respiratory failure and likely to have an elevated plasma soluble urokinase plasminogen activator receptor (suPAR)."[10][11]

Safety

It was not tested in pregnant women, but appeared to be safe in animal studies.[2]

It should not be used in people who have active infections or latent tuberculosis, who have low 白血球 counts, or who are taking TNF inhibitor（英語：TNF inhibitor）s.[2]

Adverse effects

More than ten percent of people taking Anakinra have injection site reaction（英語：injection site reaction）s, headaches, and have increased cholesterol levels.[1] Between one and ten percent of recipients have severe infections, decreased white blood cells, or decreased 血小板.[1] It is unclear if taking Anakinra increases cancer risk; studies are complicated by the fact that people with rheumatoid arthritis already face higher cancer risk.[1][4]

Chemistry

Anakinra differs from the sequence of Interleukin 1 receptor antagonist by one 甲硫氨酸 氨基酸 added to its N端; it also differs from the human protein in that it is not 醣基化, as it is 工業發酵 in 大腸桿菌.[2]

History

It was approved for medical use in the US in 2001,[2] and in the European Union in 2002.[1][3]

In 2018, NHS England（英語：NHS England） published a Clinical Commissioning Policy: Anakinra to treat periodic fevers and autoinflammatory disorders (all ages) allowing Anakinra to be commissioned as a first-line treatment for Schnitzler's syndrome（英語：Schnitzler syndrome） and in cases where the first-line treatment is not effective for Familial Mediterranean fever, Hyper-IgD syndrome（英語：Hyper-IgD syndrome） also known as Mevalonate kinase deficiency, and TNF receptor associated periodic syndrome（英語：TNF receptor associated periodic syndrome） (TRAPS),[12] and a Clinical Commissioning Policy: Anakinra/tocilizumab for the treatment of Adult-Onset Still's Disease refractory to second-line therapy (adults), allowing Anakinra to be commissioned for adult-onset Still's disease "as a third line treatment where patients are refractory to steroid-sparing effect DMARDs".[13]

In December 2020, Anakinra was approved by the US Food and Drug Administration for the treatment of deficiency of the interleukin-1–receptor antagonist（英語：deficiency of the interleukin-1–receptor antagonist） (DIRA), a rare autoinflammatory disease of infancy.[14] In 2021, it was announced that the 俄羅斯聯邦衛生部 had approved the use of Anakinra for the treatment of CAPS.[15]

In October 2021, NHS England published Clinical Commissioning Policy: Anakinra for Haemophagocytic Lymphohistiocytosis (HLH) for adults and children in all ages, allowing Anakinra to be used in the treatment of HLH（英語：haemophagocytic lymphohistiocytosis）.[16]

Society and culture

Approvals
Condition
Country RA CAPS FMF AOSD Schnitzler's MKD TRAPS DIRA HLH
US 2001 2020
UK 2018 2018 2018 2018 2021
EU 2002 2002 2002
Russia 2021

Research

Anakinra effectively treated meningitis caused by a rare genetic mutation in the gene NALP3（英語：NALP3） in a 67-year-old man enrolled in the Undiagnosed Diseases Network（英語：Undiagnosed Diseases Network）.[17] Researchers at 約翰斯·霍普金斯大學 announced in 2019 that anakinra given to pregnant mice with 茲卡病毒 had reduced fetal deaths and birth defects.[18] In November 2019, researchers at the 曼徹斯特大學 reported that Anakinra might have a use in preventing breast cancer from spreading to the bones.[19][20]

In 2021, it was reported that Anakinra appeared to reduce the 神經性疼痛 experienced by patients undergoing 化學療法 with 長春新鹼, saying that "repurposing anakinra may be an effective co-treatment strategy to prevent vincristine-induced peripheral neuropathy".[21][22]

A review published in 2022 found that "Anakinra appears to show efficacy for numerous 皮膚病學 conditions, with the strongest evidence for hidradenitis suppurativa（英語：hidradenitis suppurativa）, 貝賽特氏症, Muckle–Wells syndrome（英語：Muckle–Wells syndrome）, and SAPHO syndrome（英語：SAPHO syndrome）." and concluded that "Overall, anakinra appears to be a promising option in the treatment of numerous dermatologic inflammatory conditions refractory to first line therapies, but further and higher-quality data is needed to clarify its therapeutic role."[23]

In 2023, researchers at 哥倫比亞大學 explored the effect of Anakinra on the ageing of 造血幹細胞s in mice. They concluded "that targeting IL-1 as a key mediator of niche inflammation is a tractable strategy to improve blood production during ageing" and were reported to have said "that their findings could pave the way for science to delay aging and even lengthen the lifespan of humans".[24][25][26]

COVID-19

Anakinra is undergoing multiple clinical trials to treat 2019冠狀病毒病 patients, by targeting mechanisms in patients with hyperinflammation.[27] In 2021 a review and 元分析 of 9 studies involving 1,119 cases concluded that "Available evidence shows that treatment with anakinra reduces both the need for invasive mechanical ventilation and mortality risk of hospitalized non-intubated patients with COVID-19 without increasing the risk of adverse events."[28]

截至2021年7月 (2021-07), the 歐洲藥品管理局 (EMA) is evaluating an application to extend the use of anakinra to include treatment of 2019冠狀病毒病 in adults with pneumonia who are at risk of developing severe respiratory failure (inability of the lungs to work properly).[29] According to study results published in September 2021 in 自然-醫學, hospitalized COVID-19 patients at increased risk for 呼吸衰竭 showed significant improvement after treatment with Anakinra.[30][31]

參考

  1. ^ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8 Kineret 100 mg solution for injection in a pre-filled syringe - Summary of Product Characteristics (SmPC). UK Electronic Medicines Compendium. [2 March 2022]. （原始內容存檔於2018-03-23）. 
  2. ^ 2.0 2.1 2.2 2.3 2.4 2.5 2.6 2.7 2.8 Kineret- anakinra injection, solution. DailyMed. 30 December 2020 [2 March 2022]. （原始內容存檔於2021-07-23）. 
  3. ^ 3.0 3.1 3.2 3.3 3.4 Kineret EPAR. 歐洲藥品管理局. [20 July 2021]. （原始內容存檔於2021-07-21）.  Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  4. ^ 4.0 4.1 Singh JA, Hossain A, Tanjong Ghogomu E, Kotb A, Christensen R, Mudano AS, et al. Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis. The Cochrane Database of Systematic Reviews. May 2016, 2016 (5): CD012183. PMC 7068903  . PMID 27175934. doi:10.1002/14651858.CD012183. 
  5. ^ Gusdorf L, Lipsker D. Schnitzler Syndrome: a Review. Current Rheumatology Reports. August 2017, 19 (8): 46. PMID 28718061. S2CID 13780498. doi:10.1007/s11926-017-0673-5. 
  6. ^ Néel, Antoine; et al. Long-term effectiveness and safety of interleukin-1 receptor antagonist (anakinra) in Schnitzler's syndrome: A french multicenter study (PDF). Autoimmunity Reviews（英語：Autoimmunity Reviews）. October 2014, 13 (10): 1035–1041 [2023-02-13]. PMID 25220180. doi:10.1016/j.autrev.2014.08.031. （原始內容存檔 (PDF)於2023-02-13）. 
  7. ^ Anakinra (Kineret). American College of Rheumatology. [2021-11-22]. （原始內容存檔於2021-05-06）. 
  8. ^ EMA recommends approval for use of Kineret in adults with COVID-19. European Medicines Agency. 16 December 2021 [2 March 2022]. （原始內容存檔於2022-01-07）.  Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  9. ^ Aripaka, Pushkala; Karimi, Amna. EU regulator builds Omicron defences with approvals of GSK-Vir, Sobi drugs. Reuters. 16 December 2021 [17 December 2021]. （原始內容存檔於2022-11-06）. 
  10. ^ Sobi's Kineret granted FDA Emergency Use Authorisation for COVID-19 related pneumonia. PMNews. November 2022 [2023-02-13]. （原始內容存檔於2023-03-27）. 
  11. ^ FDA roundup. Food and Drug Administration. November 15, 2022 [2023-02-13]. （原始內容存檔於2023-03-21）. 
  12. ^ NHS England. Clinical Commissioning Policy: Anakinra to treat periodic fevers and autoinflammatory disorders (all ages) (PDF). 29 June 2018 [9 July 2018]. （原始內容存檔 (PDF)於2018-07-09）. 
  13. ^ NHS England. Clinical Commissioning Policy: Anakinra/tocilizumab for the treatment of Adult-Onset Still's Disease refractory to second-line therapy (adults) (PDF). 29 June 2018 [13 July 2018]. （原始內容 (PDF)存檔於13 July 2018）. 
  14. ^ Kaufman, Michelle B. FDA Approves New Rituximab Biosimilar & Anakinra to Treat a Rare Disease. The Rheumatologist. 2 February 2021 [4 February 2021]. （原始內容存檔於2021-02-12）. 
  15. ^ Kineret approved in Russia for the treatment of CAPS. The Pharma Letter. 17 February 2021 [18 February 2021]. （原始內容存檔於2021-11-05）. 
  16. ^ NHS England. Clinical Commissioning Policy: Anakinra for Haemophagocytic Lymphohistiocytosis (HLH) for adults and children in all ages (PDF). October 2021 [14 October 2021]. （原始內容 (PDF)存檔於13 October 2021）. 
  17. ^ Kolata G. When the Illness Is a Mystery, Patients Turn to These Detectives. The New York Times. 2019-01-07 [2019-01-09]. （原始內容存檔於2019-01-09）. 
  18. ^ Rheumatoid Arthritis Drug Diminishes Zika Birth Defects in Mice. Newsroom (Johns Hopkins Medicine). 6 May 2019 [5 September 2019]. （原始內容存檔於2019-08-23）. 
  19. ^ Arthritis drugs could be repurposed to help prevent breast cancer spreading to the bone, study suggests. Press release (University of Manchester). 20 November 2019 [21 November 2019]. （原始內容存檔於2020-09-30）. 
  20. ^ Eyre R, Alférez DG, Santiago-Gómez A, Spence K, McConnell JC, Hart C, et al. Microenvironmental IL1β promotes breast cancer metastatic colonisation in the bone via activation of Wnt signalling. Nature Communications. November 2019, 10 (1): 5016. Bibcode:2019NatCo..10.5016E. PMC 6825219  . PMID 31676788. doi:10.1038/s41467-019-12807-0. 
  21. ^ Starobova H, Monteleone M, Adolphe C, Batoon L, Sandrock CJ, Tay B, et al. Vincristine-induced peripheral neuropathy is driven by canonical NLRP3 activation and IL-1β release. The Journal of Experimental Medicine. May 2021, 218 (5): e20201452. PMC 7933984  . PMID 33656514. doi:10.1084/jem.20201452. 
  22. ^ Chemotherapy with fewer side effects may be on the way. University of Queensland. 15 March 2021 [15 March 2021]. （原始內容存檔於2021-03-15）. 
  23. ^ Tegtmeyer, Kyle; et al. Off-Label studies on anakinra in dermatology: a review. Journal of Dermatological Treatment（英語：Journal of Dermatological Treatment）. 2 January 2022, 33 (1): 73–86. PMID 32279586. S2CID 215749189. doi:10.1080/09546634.2020.1755417. 
  24. ^ Caler, Luigi. This Arthritis Drug Could Rejuvenate Blood In The Elderly, Delay Aging. Medical Daily. 1 February 2023 [6 February 2023]. （原始內容存檔於2023-06-01） （英語）. 
  25. ^ Mitchell, Carl A.; Verovskaya, Evgenia V.; Calero-Nieto, Fernando J.; Olson, Oakley C.; Swann, James W.; Wang, Xiaonan; Hérault, Aurélie; Dellorusso, Paul V.; Zhang, Si Yi; Svendsen, Arthur Flohr; Pietras, Eric M.; Bakker, Sietske T.; Ho, Theodore T.; Göttgens, Berthold; Passegué, Emmanuelle. Stromal niche inflammation mediated by IL-1 signalling is a targetable driver of haematopoietic ageing. Nature Cell Biology. January 2023, 25 (1): 30–41 [2023-02-13]. ISSN 1476-4679. doi:10.1038/s41556-022-01053-0. （原始內容存檔於2023-02-15） （英語）. 
  26. ^ Irving M. Arthritis drug mimics "young blood" transfusions to reverse aging in mice. New Atlas. 6 February 2023 [6 February 2023]. （原始內容存檔於2023-08-08）. 
  27. ^ Anakinra in COVID-19: important considerations for clinical trials. Press release. May 2020 [5 January 2021]. （原始內容存檔於2021-12-16）. 
  28. ^ Barkas, Fotios; Ntekouan, Sebastian Filippas; Kosmidou, Maria; Liberopoulos, Evangelos; Liontos, Angelos; Milionis, Haralampos. Anakinra in hospitalized non-intubated patients with coronavirus disease 2019: a systematic review and meta-analysis. Rheumatology. 2021-05-17, 60 (12): 5527–5537. PMC 8194671  . PMID 33999135. doi:10.1093/rheumatology/keab447. 
  29. ^ EMA starts evaluating the use of Kineret in adult COVID-19 patients at increased risk severe respiratory failure. 歐洲藥品管理局 (EMA) (新聞稿). 16 July 2021 [20 July 2021]. （原始內容存檔於2021-07-21）. 
  30. ^ Kyriazopoulou, Evdoxia; Poulakou, Garyfallia; Milionis, Haralampos; Metallidis, Simeon; Adamis, Georgios; Tsiakos, Konstantinos; Fragkou, Archontoula; Rapti, Aggeliki; Damoulari, Christina; Fantoni, Massimo; Kalomenidis, Ioannis. Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial. Nature Medicine. 2021-09-03, 27 (10): 1752–1760. ISSN 1078-8956. PMC 8516650  . PMID 34480127. doi:10.1038/s41591-021-01499-z  . 
  31. ^ Anakinra improved survival in hospitalized COVID-19 patients. www.mdedge.com. [2021-09-09]. （原始內容存檔於2021-11-05）. 

外部鏈接

  • Anakinra. Drug Information Portal. U.S. National Library of Medicine. [2023-02-13]. （原始內容存檔於2022-11-26）. 
取自「https://zh.wikipedia.org/w/index.php?title=阿那白滯素&oldid=79394850」